Skip to main content

Recent articles

Blueprint still sees an oncology future

Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.

GSK’s $625m TIGIT bet approaches crunch time

Readout of the delayed Galaxies Lung-201 study is due imminently.

Boehringer: what’s in and what’s out?

A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.

Microbiome make or break time for MaaT Pharma

The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.

Astra starts a pivotal lung cancer combo

Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.

FibroGen hopes to buck its pamrevlumab trend

Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.